InMed Pharmaceuticals reported strong Q1 FY2025 results with BayMedica commercial business generating revenues of $1.3M, up 40% YoY, and achieving a net income of $0.3M. The company's cash position stood at $5.6M as of September 30, 2024, expected to fund operations through Q1 2025.The company's Alzheimer's treatment candidate, INM-901, showed significant progress with positive behavioral data from long-term preclinical studies. The drug demonstrated therapeutic brain levels through oral administration, comparable to intraperitoneal injection. Further molecular analyses results are expected in Q4 2024.Research and development expenses decreased to $0.8M from $1.3M YoY, primarily due to reduced external contractor costs and patent fees. The company implemented a reverse stock split effective November 14, 2024, to maintain Nasdaq compliance while exploring strategic opportunities to enhance shareholder value.

InMed Pharmaceuticals reported strong Q1 FY2025 results with BayMedica commercial business generating revenues of $1.3M, up 40% YoY, and achieving a net income of $0.3M. The company's cash position stood at $5.6M as of September 30, 2024, expected to fund operations through Q1 2025.The company's Alzheimer's treatment candidate, INM-901, showed significant progress with positive behavioral data from long-term preclinical studies. The drug demonstrated therapeutic brain levels through oral administration, comparable to intraperitoneal injection. Further molecular analyses results are expected in Q4 2024.Research and development expenses decreased to $0.8M from $1.3M YoY, primarily due to reduced external contractor costs and patent fees. The company implemented a reverse stock split effective November 14, 2024, to maintain Nasdaq compliance while exploring strategic opportunities to enhance shareholder value.